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The bacterial formation of trimethylamine (TMA) has been linked to cardiovascular disease. This review
focuses on the methods employed to investigate the identity of the bacteria responsible for the formation
of TMA from dietary choline and carnitine in the human gut. Recent studies have revealed the metabolic
pathways responsible for bacterial TMA production, primarily the anaerobic glycyl radical-containing,
choline-TMA lyase, CutC and the aerobic carnitine monooxygenase, CntA. Identification of these enzymes
has enabled bioinformatics approaches to screen both human-associated bacterial isolate genomes and
whole gut metagenomes to determine which bacteria are responsible for TMA formation in the human
gut. We centre on several key methodological aspects for identifying the TMA-producing bacteria and
report how these pathways can be identified in human gut microbiota through bioinformatics analysis
of available bacterial genomes and gut metagenomes.
 2018 The Authors. Published by Elsevier Inc. This is an openaccess article under the CCBY license (http://
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The human gastro-intestinal tract is an ecosystem rich in micro-
bial diversity. Gut microbiota encompasses diverse groups of bac-
teria, archaea, viruses, fungi and other microeukaryotes [1–5]. It
has been estimated that, on average, 3.8  1013 bacteria inhabit
the human gut, which encompasses over 1000 species [6,7]. It is
now evident that gut microbiota have an important role in human
health and disease. In a healthy gut, these microbes form a stable
community whereas during gut dysbiosis, opportunistic pathogens
and parasites thrive [8]. Understanding the complex interactions
and metabolic capacity of the gut microbiome will help us toexamine the workings of this microbiome and better manage
disease.
Recent work on the role of the human gut microbiome in dis-
ease has linked the bacterial metabolite trimethylamine (TMA)
with atherosclerotic cardiovascular disease (ACVD). Previous stud-
ies on humans and experimental animals have indicated that cho-
line and carnitine, both of which are conditional B-type vitamins,
are the major dietary precursors of TMA in the gut [9–17]. TMA for-
mation from choline and carnitine is linked to ACVD through hep-
atic formation of trimethylamine N-oxide (TMAO) although the
underlying molecular and cellular mechanisms remain to be fully
established [9,15,18].
The metabolic pathways responsible for bacterial transforma-
tion of choline and carnitine to TMA were unknown until very
recently [10,17]. It is interesting that choline and carnitine
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requires a glycyl radical, encoded in the choline-TMA lyase, CutC
protein for the breakage of the carbon-nitrogen bond, whereas
the latter employs a mononuclear iron in the active centre in the
CntA protein. CutC belongs to a larger family of enzymes sharing
the same glycyl radical chemistry and shows significant sequence
homology to other members of the family such as glycerol dehy-
dratase and pyruvate formate lyase [10,19]. Similarly, CntA is a
new member of the Rieske-containing oxygenases and has signifi-
cant sequence homology to several members of the Rieske protein
family [17]. Although the enzymes responsible for TMA formation
from these compounds have now been established, identifying of
the microbiota species in the human gut that are responsible for
TMA formation remains a challenging task. We focus on several
key methodological aspects, which require particular attention
when identifying the TMA-producing bacteria and report how to
identify these TMA-production pathways in the human gut micro-
biome through analyses of published bacterial genomes and
microbiomes.
2. Pathways of TMA production by gut microbiota
Several pathways for bacterial TMA formation are currently
known (Fig. 1), involving a choline-TMA lyase, CutC [10,19], a car-Fig. 1. Known pathways for the formation of trimethylamine (TMA) from dietary cholin
figure are: CntAB, carnitine monooxygenase [17] which is analogous to YeaW; CutCD, c
betaine is mediated by the Bet pathway [48], a pathway from carnitine to glycine betaine
grey the TorA, trimethylamine N-oxide reductase [21] and TMAO formation pathway FMO
of this review [51,52].nitine monooxygenase, CntAB [17], a glycine betaine reductase,
GrdH [20], or additionally via the reduction of TMAO [21–23]. Here
we focus on the production of TMA from choline and carnitine,
since they have been shown to be relevant in cardiovascular dis-
ease [9,24]. These two pathways have been determined using a
combination of comparative omics, bioinformatics, molecular
genetics and biochemistry based on several model laboratory bac-
terial strains [10,17,19].
The enzyme that catalyses the degradation of choline to TMA
under anaerobic conditions has been identified as the glycyl
radical-containing enzyme CutC [10,19]. Interestingly, the cut gene
cluster also houses a set of genes encoding a microcompartment
[10,19]. Although the cut gene cluster was originally characterized
from a sulfate-reducing deltaproteobacterium, Desulfovibrio desul-
furicans [10], subsequent analyses have shown that cutC homo-
logues and the shell proteins involved in microcompartment
formation also occurred in gut Gammaproteobacteria, Actinobacteria
and Firmicutes [12,19,25]. The formation of a functional microcom-
partment in choline metabolism has been experimentally demon-
strated in Proteus mirabilis [19].
Further to the Cut pathway, it has been previously hypothesized
that other pathways capable of degrading choline to TMA may also
exist, as exemplified by Edwardsiella tarda ATCC 23685. It has been
demonstrated that although this bacterium was capable ofe and carnitine. The key enzymes responsible for TMA production indicated in the
holine-TMA lyase [10] and GrdH, glycine betaine reductase [20]. Choline to glycine
has been proposed, but has yet to be elucidated [49,50]. Additionally shown in dark
, flavin-containing monooxygenase are critical to TMA cycling, but are not the focus
Fig. 2. A sequence alignment of characterized CutC proteins from Klebsiella pneumonia [34], Desulfovibrio alaskensis [35] and Proteus mirabilis [19] aligned with Clustal Omega
[53] to blast matching genes from Edwardsiella tarda. Despite showing a global high matching sequence similarity, when we compare the key binding site residues (coloured),
we observe very little concensus. Sequences are visualised in JalView [54].
Fig. 3. A. Protein alignment of CntA and YeaW showing sequence conservation of the functional domains based on representative CntA sequences from functional confirmed
Citrobacter freundii CntA, Acinetobater baumanii CntA, Escherichia coli CntA and Escherichia coli YeaW. The alignment shows a high level on sequence conservation between
CntA sequences and the functional domain of YeaW is indistinguishable. B. Phylogenetic tree of Rieske oxygenases based on full length protein sequences with bootstrap
values. A. and B. combined show that the CntA from Escherichia coli SE11 [17] and YeaW from Escherichia coli DH10B [26,27] have an identical protein sequence. CntA of
Citrobacter freundii and Acinetobater baumanii cluster with the other CntA proteins and are separate from other Rieske oxygenases used as outgroups.
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cut gene cluster [14]. A close examination of the recently published
genomes of Edwardsiella tarda has revealed the presence of several
glycyl radical family proteins (Edwardsiella tarda ATCC 23685
EDWATA_00359: E-value 9e-136; identity 33% to characterized
CutC of P. mirabilis [19]), which are annotated as pyruvate-
formate lyases (EC: 2.3.1.54) (Fig. 2). However the key choline-
binding site residues showed very low consensus to confirmed
CutC proteins (Fig. 2). It therefore remains to be tested whether
these so-called pyruvated-formate lyases are functional choline-
TMA lyases, or indeed a novel glycyl radical-independent pathway
exists in Edwardsiella tarda for choline degradation to TMA.An aerobic pathway for the degradation of carnitine to TMA has
been identified by our groups using Acinetobacter baumannii as a
model. The enzyme, carnitine monooxygenase encoded by the cntA
gene, represents a novel protein of the Rieske oxygenase family,
which is best known for several enzymes involved in the oxidation
of aromatic compounds [17]. In Escherichia coli and closely related
bacteria, CntA is sometime also referred as YeaW in the literature
[26]. YeaW is sometimes described as a novel enzyme targeting
c-butyrobetaine [27], however, we and others have shown that
E. coli YeaW is homologous to the CntA of A. baumannii through
phylogenetic analysis, PFAM domain analyses and substrate
specificity tests (Fig. 3) [28–30]. The CntA enzyme has been
Table 1
Bacterial strains confirmed to degrade choline or carnitine to TMA and containing either the cutCD or cntAB pathways respectively.
Organism Reference Choline Carnitine
Proteobacteria Acinetobacter baumannii (ATCC 19606) Zhu 2014 [17] +
Acinetobacter calcoaceticus (ATCC 39647) Ditullio 1994 [56] +
Acinetobacter calcoaceticus 69/V Kleber 1977 [57] +
Citrobacter freundii 4_7_47CFAA +
Desulfovibrio alaskensis G20 Weimer 1988 [58] +
Desulfovibrio desulfuricans (ATCC 27774) Craciun 2012 [10] +
Desulfovibrio desulfuricans subsp. aestuarii (DSM 17919) Rath 2017 [29] +
Escherichia coli BL21-DE3 Kalnins 2018 [28] +
Escherichia coli DH10b Koeth 2014 [24] +
Escherichia coli K12 (DSM 10517) Rath 2017 [29] +
Escherichia coli MS 200-1 Romano 2017 [59] +
Escherichia coli MS 69-1 Campo 2015 [12] +
Escherichia coli SE11 Zhu 2014 [17] +
Escherichia fergusonii (ATCC 35469) Romano 2015 [14] +
Klebsiella pneumoniae (MSCL 535) Kuka 2014 [16]/Kalnins 2018 [28] +
Klebsiella pneumoniae (MSCL) Kalnins 2015 [35] +
Klebsiella sp. MS 92-3 Campo 2015 [12] +
Pelobacter acetylenicus Schink 1985 [34] +
Pelobacter carbinolicus Aklujkar 2012 [33] +
Proteus mirabilis (ATCC 29906) Campo 2015 [12] +
Proteus mirabilis (DSM 4479) Jameson 2016 [19] +
Proteus mirabilis BB2000 Campo 2015 [12] +
Proteus mirabilis HI4320 Campo 2015 [12] +
Proteus penneri (ATCC 35198) Romano 2015 [14] +
Proteus vulgaris Seim 1982 [60] +
Providencia rettgeri (DSM 1131) Romano 2015 [14] +
Providencia rettgeri (MSCL 730) Kalnins 2018 [28] +
Serratia marcescens (MSCL 1476) Unemoto 1966 [61]/Kalnins 2018 [28] +
Vibrio cholinicus Hayward 1959 [62] +
Firmicutes Anaerococcus hydrogenalis (DSM 7454) Romano 2015 [14] +
Clostridium asparagiforme (DSM 15981) Romano 2015 [14] +
Clostridium citroniae WAL-17108 Campo 2015 [12] +
Clostridium hathewayi (DSM 13479) Rath 2017 [29] +
Clostridium hathewayi (DSM 13749) Romano 2015 [14] +
Clostridium sporogenes (ATCC 15579) Romano 2015 [14] +
Streptococcus dysgalactiae (ATCC 12394) Campo 2015 [12] +
Actinobacteria Olesnella uli (DSM 7084) Campo 2015 [12] +
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teobacteria, Actinobacteria and Firmicutes [17,27,31,32].3. Identification of TMA formation potential in bacterial isolates
One of the most widely-used and simplest approaches to iden-
tify gut-associated microbes with the potential to metabolise cho-
line and carnitine to TMA is in silico BLAST searches of the key
signature genes against microbial genome databases such as IMG
(https://img.jgi.doe.gov/cgi-bin/m/main.cgi) and NCBI [12,29].
BLAST searches are carried out using single amino acid sequences
of a key gene (with a proven function, Table 1) as the query and
comparing this, by means of local alignments, to all of the
sequences in a given database. The BLAST searches result in hits
to similar gene sequences and provides measures of their statisti-
cal significance and can be carried out directly through databasesFig. 4. Alignment of the cut gene clusters for bacterial isolates representative of the thr
regions of the glycyl radical enzyme (GRE), cutC and activating enzyme, cutD. Gene funcsites such as IMG and NCBI. Using key genes from the choline
(cutC) and carnitine (cntA) to TMA pathways as BLAST search
queries, a number of hits, or gene homologues, can be identified
in fully sequenced human-associated bacterial genomes. However,
caution must be used when using this approach. It has been well-
documented that the presence of a cutC homologue alone is insuf-
ficient to predict choline usage, due to a number of closely related
genes with different substrate specificity, even within a single bac-
terial genome [12,14,19,29,32]. The gene synteny of the cut cluster
provides a genetic context [12], the presence of the activator
enzyme gene (cutD) and microcompartment genes, in addition to
cutC, may be a better predictor of function in genome sequenced
bacteria than cutC alone (Fig. 4). Again, this approach is not with-
out pitfalls. It has been documented that several microbial species
of the Pelobacter genus can metabolism choline to TMA [33,34] and
yet the genomes do not appear to contain microcompartment
genes in the neighborhood of the cutC/D genes. Alternatively theee choline-TMA lyase (cutC) types [19]. The clusters are aligned to the homologous
tions are denoted by colour and the legend shown at the bottom.
Fig. 5. The active site of CutC choline-trimethylamine lyase from Klebsiella
Pneumoniae (PDB 5A0U) showing the key residues involved in substrate recognition
and enzymatic activity, visualised in Chimera [55].
46 E. Jameson et al. /Methods 149 (2018) 42–48protein structure is available for CutC (Fig. 5), which would help to
determine the active site, enabling the validation of choline-
binding CutC (Fig. 2) [35,36].
It is important to note that such homology based phylogenetic
analysis of cutC and cntA in bacterial isolates takes us one step
away from the functionally verified genes and inevitably intro-
duces margins for errors. The identified homologues may or may
not encode a functional enzyme and additional experiments (e.g.
by heterologous expression in a non-TMA producer) are required
to validate the functionality of CutC/CntA proteins in TMA forma-
tion [10,17,19]. Wherever it is possible to obtain the bacterial iso-
late, the bacterium’s ability to produce TMA from choline should be
experimentally tested [10,17].
4. Identification of TMA formation potential in microbiome
studies
Recent studies have begun to resolve which microbial species
are responsible for TMA formation and degradation in the human
gut through analysis of metagenomic datasets
[12,29,31,32,37,38]. This approach has involved analysing existing
human gut metagenomes in search of key TMA metabolic genes
[31,32], screening fecal samples for the presence of these key genes
[12,29] or sequencing the faecal microbiomes of patients suffering
with atherosclerotic cardio vascular disease [37].
To screen existing human gut metagenomes for TMA-
production pathways and TMA-degradation pathways, metagen-
ome data can be retrieved from public repositories, such as MG-
RAST (http://metagenomics.anl.gov/) or specific metagenomes,
such as the Karlsson data set (http://sra.dnanexus. com/studies/
SRP016067) [29,31,32,38]. Alternatively, Jie et al. [37] undertook
targeted clinical sample collection, focusing on the fecal metagen-
ome of ACVD patients to link the gut microbiome and TMA-
production pathways with ACVD [39]. The primary methods uti-
lised to identify TMA-production pathways frommetagenome data
are BLAST and Profile Hidden Markov Models (profile-HMM)
[29,31,32]. The basis of BLAST (see Section 3) is a single represen-
tative amino acid sequence, while profile-HMMs, adapted origi-
nally from speech recognition algorithms, use multiple alignedamino acid sequences that are representative of a key enzyme or
a specific protein family. The profile-HMMs rely on probabilistic
models and take into account key amino acids and gaps, rather
than identifying the percentage match of an entire sequence, as
BLAST does. The two alternate methods have different advantages,
BLAST only requires a single confirmed sequence, while profile-
HMMs are based on the conserved motifs within a functional pro-
tein family, which reduces the bias innate to the BLAST approach
[40]. BLAST and profile-HMM searches can be carried out locally
using BLAST+ (NCBI) and HMMER (hmmer.org), respectively. After
generating BLAST or profile-HMM hits it is crucial to reduce false
positive hits, to homologues with unrelated functions, which can
account for >90% of the total hits. This can be achieved through
phylogenetic comparison of the hits to reference strains with
known functions [31]. Likewise false negatives can further confuse
results, e.g. assigning cutC homologues as pyruvate-formate lyase
may account for results of Jie et al. [37], who report that ACVD
patients had a significantly higher incidence of cntA than cutC (con-
trary to previous findings [29,31,32]), and a significant enrichment
of pyruvate-formate lyase homologues. Wherever possible, one
should 1) examine the key signature residuces of metagenome-
derived CutC/CntA for substrate co-ordinnation; 2) confirm the
function of metagenome-derived CutC/CntA by over-expression
in a foreign hosts; and 3) obtain the (most closely related) bacterial
isolate and test the bacterium’s ability to produce TMA [10,17].
An alternative approach to using metagenome data is to utilise
the abundant 16S rRNA gene sequencing data available and infer
microbiome function, i.e. TMA degradation, based on taxonomy.
There are various programs available, such as PICRUSt [41], Tax4-
Fun [42], Piphillin [43] and Vikodak [44] that aim to predict func-
tion from 16S rRNA gene sequences. These allow the user to get an
idea of the potential metabolic function of a microbial community.
The function prediction programs rely on how accurate and com-
prehensive the databases are, fortunately for studying the human
gut, these programs have been developed using the human micro-
biome project and gut microbiome databases are sufficiently com-
prehensive, resulting in 75–85% average correlations to
metagenome data, at predicting community level functions
[3,41–44]. Another consideration for specific functions is how
evenly distributed the functions of interest are across bacterial
families or genera. Matching 16S rRNA gene taxonomy and meta-
bolic function can be difficult to reconcile for some functions,
due to gene loss between closely related strains and lateral gene
transfer [45,46]. The carnitine degradation genes cntAB have been
detected in Proteobacteria, while the choline degradation cutCD
genes have been detected in Proteobacteria, Firmicutes and Acti-
nobacteria (Table 1), however these functional genes are unevenly
distributed between bacterial phyla preventing accurate prediction
of function through 16S rRNA genes alone [10,12,32]. PICRUSt has
been applied to predict significant differences in genes involved in
choline, carnitine and trimethylamine (TMA) metabolism in
chronic kidney disease gut microbiomes [47], however these pre-
dictions should inform, rather than replace shotgun metagenome
sequencing for accurate analysis of metabolic functions in a
community.5. Summary
In the rapidly developing and expanding field of gut
microbiome-associated disease, microbial approaches are vital to
understanding the causes of disease and the complex community
interactions. The identification of metabolic pathways responsible
for TMA production has informed molecular and clinical
approaches that identify the species responsible for generating
TMA in the human gut. A more in-depth understanding of these
E. Jameson et al. /Methods 149 (2018) 42–48 47processes and an exhaustive identification of all bacterial TMA-
production pathways will help to complete the picture of gut
microbiome structure and function in terms of TMA-related dis-
ease pathogenesis. Direct links between diet, bacterial communi-
ties and human disease have been discovered, through a
combination of molecular microbial approaches, these tools pave
the way for future studies to expand the field of human micro-
biome caused disease.Acknowledgements
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